Cardiovascular safety of strontium ranelate: Real-life assessment in clinical practice

Osteoporosis International

Volumn 25, Issue 2, 2014, Pages 397-398

  Donneau, A F ^a   Reginster, J Y ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

STRONTIUM RANELATE; BONE DENSITY CONSERVATION AGENT; THIOPHENE DERIVATIVE;

CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; COMORBIDITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; HEART FAILURE; HEART INFARCTION; HUMAN; OSTEOPOROSIS; PERIPHERAL VASCULAR DISEASE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; EUROPEAN UNION;

BONE DENSITY CONSERVATION AGENTS; CARDIOVASCULAR DISEASES; EUROPEAN UNION; HUMANS; OSTEOPOROSIS; PHARMACOVIGILANCE; THIOPHENES;

EID: 84899112815     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2583-3     Document Type: Editorial

References (8)

1. European Medicines Agency (2012) Good pharmacovigilance practices. Available at: www.ema.europa.eu. Accessed 4 November 2013
2. European Medicines Agency (2013) PSUR assessment report for strontium ranelate. Available at: www.ema.europa.eu. Accessed 4 November 2013
3. Cooper C, Fox KM, Borer JS (2013) Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD. Osteoporos Int. doi:10.1007/s00198-013-2582-4
4. Abrahamsen B, Grove EL, Vestergaard P (2013) Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with stronium ranelate. Osteoporos Int. doi:10.1007/s00198-013-2469-4
5. Cooper C, Reginster JY, Cortet B et al (2012) Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr Med Res Opin 28:475-491
6. Rizzoli R, Reginster JY, Boonen S et al (2011) Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int 89:91-104
7. Rizzoli R, Reginster JY (2011) Adverse drug reactions to osteoporosis treatments. Expert Rev Clin Pharmacol 4:593-604
8. Kanis JA, McCloskey EV, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23-57